

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Audited Standalone Financial Results for the Year Ended 31st March 2019 and for the Quarter ended and Consolidated for the Year ended prepared in Compliance with the Indian Accounting Standard (IND AS)

PART I		(Rs. In Lakhs) except EPS						
		Quarter ended			Year ended		Consolidated Year ended	
Sl.No	Particulars	3 months ended (31-03-2019)	3 months ended (31-12-2018)	3 months ended (31-03-2018)	Year to date Upto (31-03-2019)	For the Previous Year ended (31-03-2018)	Consolidated as on 31st March 2019	Consolidated as on 31st March 2018
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
I	Revenue From operations	949.48	1,307.49	1,652.27	4,335.89	4,717.07	4,335.89	4,717.07
II	Other Income	28.63	31.01	93.49	65.36	122.80	65.36	129.44
II (a)	Profit on sale of Investments	-	-	-	-	3,003.64	-	3,003.64
III	Total Income (I+II)	978.12	1,338.50	1,745.76	4,401.25	7,843.51	4,401.25	7,850.15
IV	EXPENSES							
a)	Cost of materials consumed	742.04	961.26	1,290.93	3,329.44	2,680.07	3,329.44	2,681.04
b)	Purchases of Stock-in-Trade	15.68	(0.00)	600.44	46.36	1,298.95	46.36	1,298.95
c)	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	139.24	(70.19)	(44.44)	81.14	409.20	81.14	409.20
d)	Employee benefits expense	267.08	221.99	228.50	901.29	747.49	901.29	747.49
e)	Finance costs	21.16	46.35	102.20	212.64	680.53	212.66	694.29
f)	Depreciation and amortization expenses	76.72	90.22	76.69	342.17	364.59	347.62	397.41
g)	Other expenses	1,073.02	77.21	2,861.38	1,311.18	3,090.24	1,312.03	3,093.43
	Total expenses (IV)	2,334.94	1,326.83	5,115.69	6,224.22	9,271.08	6,230.53	9,321.82
V	Profit/(loss) before exceptional items and tax (I-IV)	(1,356.82)	11.67	(3,369.93)	(1,822.97)	(1,427.56)	(1,829.28)	(1,471.66)
VI	Exceptional Items	-	-	-	-	-	(100.99)	-
VII	Profit/ (loss) before exceptions items and tax(V-VI)	(1,356.82)	11.67	(3,369.93)	(1,822.97)	(1,427.56)	(1,728.29)	(1,471.66)
VIII	Tax expense:							
	(1) Current tax	-	-	-	-	-	-	-
	(2) Deferred tax	149.36	(0.43)	46.80	150.07	217.52	106.74	219.27
IX	Profit (Loss) for the period from continuing operations	(1,506.19)	12.10	(3,416.72)	(1,973.04)	(1,645.09)	(1,835.03)	(1,690.93)
X	Profit/(loss) from discontinued operations	-	-	-	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(1,506.19)	12.10	(3,416.72)	(1,973.04)	(1,645.09)	(1,835.03)	(1,690.93)
	Other Comprehensive Income							
	A. (i) Items that will not be reclassified to profit or loss (Minority Interest)	-	-	-	-	-	(52.01)	17.28
XIV	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	(1,506.19)	12.10	(3,416.72)	(1,973.04)	(1,645.09)	(1,887.04)	(1,673.65)
XVI	Earnings per equity share (for continuing operation):							
	(1) Basic	(6.37)	0.05	-	(8.34)	(6.95)	(11.44)	(9.24)
	(2) Diluted	(6.37)	0.05	-	(8.34)	(6.95)	(11.44)	(9.24)
XVII	Earnings per equity share (for discontinued operation):							
	(1) Basic	-	-	-	-	-	-	-
	(2) Diluted	-	-	-	-	-	-	-
XVIII	Earning per equity share (for discontinued & continuing operation)							
	(1) Basic	(6.37)	0.05	-	(8.34)	(6.95)	(11.44)	(0.11)
	(2) Diluted	(6.37)	0.05	-	(8.34)	(6.95)	(11.44)	(0.11)

Notes

1) The audited financial statements for the quarter and year ended 31 March 2019 was reviewed by the Audit Committee and approved and authenticated by the Board of Directors at their meeting held on 27th May 2019. The information presented above is extracted from the audited standalone financial statements. The audited financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

2. The Company operates only in one segment, i.e. Pharmaceutical formulations, as such reporting is done on a single segment basis.

3. The above figures have been regrouped and Re-arranged Wherever considered necessary.

4. The figures of the Quarter are the balancing figures in respect of the Financial year and the published year to date figures upto the Fourth quarter of the Financial year.

5. In view of the Stay of the implementation of the approved Resolution Plan by the NCLAT, New Delhi. No Restatements of Assets and Liabilities (As per Approved Resolution Plan) in the financial statements is considered during the financial year 2018-19. The process of restructuring of fair values of assets and liabilities detailed in the Resolution Plan and restatement thereof in the accounts is being deferred to be carried out in the ensuing Financial Year.

For BAFNA PHARMACEUTICALS LIMITED

BAFNA MAHVEER CHAND
MANAGING DIRECTOR
DIN:01458211



Place: Chennai
Date: 27.05.2019

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)
Statement of Assets & Liabilities as at 31 March 2019

Particulars	Standalone (Rs. In Lakhs)		Consolidated (Rs. In Lakhs)	
	As At 31 March 2019	As At 31 March 2018	As At 31 March 2019	As At 31 March 2018
ASSETS				
Non-current assets				
(a) Property Plant and Machinery	3,701.90	3,993.67	3,701.90	4,486.04
(b) Capital Work- In- Progress	-	-	-	-
(c) Investment Property	-	-	-	-
(d) Good Will	-	-	3.58	3.58
(e) Other Intangibles	-	-	-	-
(f) Intangibles Assets Under Development	-	-	-	-
(g) Bio-Logical Assets other bearer plants	-	-	-	-
(h) Financial Assets				
(i) Investments	143.00	143.00	-	-
(ii) Trade Receivables	-	-	-	-
(iii) Loans	-	-	-	-
(iv) Others	3,295.33	3,732.79	3,295.33	4,419.55
(i) Deferred Tax Assets (Net)	-	-	-	-
(j) Other Non- Current Asset	99.50	53.16	99.50	53.16
(k) Minority Interest	-	-	-	-
Current assets				
(a) Inventories	928.23	1,067.42	928.23	1,067.42
(b) Financial Assets				
(i) Investments	-	-	-	-
(ii) Trade Receivables	2,483.37	2,427.94	2,483.37	2,427.94
(iii) Cash and Equivalentents	270.19	270.40	271.32	295.12
(iv) Bank Balances other(iii) above	-	-	-	-
(iv) Loans	-	-	-	-
(v) Others	1,142.44	1,063.17	1,163.98	1,083.43
(c) Current Tax Assets	-	-	-	-
(c) other Current assets	-	-	-	-
Total - Assets	12,063.97	12,751.55	11,947.21	13,836.24
EQUITY AND LIABILITIES - Equity				
(a) Equity Share capital	2,365.63	2,365.63	2,365.63	2,365.63
(b) Other Equity	(286.32)	1,686.73	(459.81)	1,427.24
(c) Equity Share Warrants	-	-	-	-
Equity Attributable to Equity Shareholders				
(d) Non- Controlling Interest	-	-	(20.61)	(72.63)
LIABILITIES				
1. Non-current liabilities				
(a) Financial Liabilities				
(i) Borrowings	2,298.82	2,324.94	2,298.82	2,324.94
(ii) Trade Payables	-	-	-	-
(iii) other Financial Liabilities	-	-	-	-
(b) Provisions	-	-	-	-
(c) Deferred Tax Liabilities	617.87	467.80	617.87	511.13
(d) other non- current Liabilities	3.00	3.00	63.22	1,295.25
2 Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	2,323.97	2,329.10	2,323.97	2,329.10
(ii) Trade Payables	3,942.40	2,782.49	3,955.86	2,861.02
(iii) other Financial Liabilities	-	-	-	-
(b) other current Liabilities	798.58	791.86	802.27	794.56
(c) Provisions	-	-	-	-
(d) Current Tax Liabilities (Net)	-	-	-	-
Total - Equity and Liabilities	12,063.97	12,751.55	11,947.21	13,836.24

